Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor

IntroductionImmune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota composition in...

Full description

Bibliographic Details
Main Authors: Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda, Kiyoshi Yoshimura
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
clinical efficacy
gut microbiota
immune checkpoint inhibitors
immune-related adverse events
PD-1 inhibitor
Turicibacter
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1164724/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1164724/full

Similar Items